Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject/legal representative is considered reliable and capable of adhering to the protocol~* Subject has remained seizure free and completed the Maintenance Phase of the SP0993; or subject has experienced 1 or more seizures on the first or second target dose during the SP0993 Maintenance Phase~* Subject is expected to benefit from participation in SP0994 in the opinion of the investigator~Exclusion Criteria:~* Subject is receiving any investigational drugs or using any experimental devices in addition to LCM or CBZ-CR~* Subject experienced a seizure at the third target dose during the Evaluation Phase or Maintenance Phase of the SP0993 study~* Subject is taking benzodiazepines for a non-epilepsy indication~* Subject meets a withdrawal criterion from the previous study SP0993~* Subject is experiencing an ongoing SAE from the previous study SP0993~* Subject has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response (Yes) to either Question 4 or Question 5 of the Columbia Suicide Severity Rating Scale (C-SSRS) at Screening. Or subject has a positive response (Yes) to either Question 4 or Question 5 of the C-SSRS at Screening in the Since Last Visit version

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lacosamide (Type: EXPERIMENTAL): 50 and 100 mg tablets of Lacosamide given as 100 mg/day, 200 mg/day, 300 mg/day, 400 mg/day, 500 mg/day or 600 mg/day throughout the Treatment Period (Maximum 3.5 Years)
- Carbamazepine-Controlled Release (CBZ-CR) (Type: ACTIVE_COMPARATOR): 200 mg tablets of Carbamazepine-CR given as 200 mg/day, 400 mg/day, 600 mg/day, 800 mg/day, 1000 mg/day or 1200 mg/day throughout the Treatment Period (Maximum of 3.5 Years)

Based on this trial design, predict the completion outcome and termination type (if applicable).